Thales

Thales™ is an end-to-end quantitative systems pharmacology (QSP) modeling platform developed by Simulations Plus, designed to support the full lifecycle of QSP workflows—from model construction and SimPops® optimization to simulation visualization and results analysis. It is built for pharmaceutical and biotech teams working at industrial scale, where delivering clinically relevant, large-scale QSP simulations demands an integrated, standardized, and efficient approach to managing biological complexity, population-level predictions, and model customization.

By providing a unified environment that embraces the ever-changing nature of biological knowledge, Thales makes model updates cheaper and easier, enabling researchers to test drug candidates for clinical efficacy and toxicity potential, understand biological complexities, and guide clinical trial designs and optimal dosing protocols across multiple data scales—from in vitro assay data to clinical endpoints.

Core Platform Capabilities

• Clear and Unambiguous Model Specification: A standardized set of modeling building blocks ensures models are precisely defined and reproducible across teams.
• Modular Design and Reusability: Components can be reused and recombined, reducing redundant effort and accelerating model development.
• Population-Centric Capabilities: Supports generation and optimization of SimPops® (simulated populations) calibrated to real clinical data, enabling population-level predictions.
• Seamless Integration and Replication of Clinical Trial Protocols: Simulation pipelines allow users to readily implement virtual clinical trial protocols within the platform.
• Automated Parameter Calibration: Streamlines the process of fitting model parameters to observed data, reducing manual effort and improving accuracy.
• Built-In Sensitivity and Parameter Analysis Tools: Enables quantification of uncertainty and systematic exploration of parameter space to strengthen model confidence.
• Robust Documentation and Transparency: Supports audit-ready, well-documented modeling workflows that promote scientific rigor.
• Interoperability and Standardization: Designed to contribute to QSP standardization efforts, facilitating data and model exchange across platforms and organizations.
• User Interface Features: Provides visualization and analysis tools to examine and communicate simulation results effectively.

Pre-Validated QSP Models Available

• Obesity
• Atopic dermatitis
• Dermatomyositis
• Inflammatory bowel disease (ulcerative colitis and Crohn's disease)
• Psoriasis and psoriatic arthritis
• Rheumatoid arthritis
• Lupus (systemic lupus erythematosus and cutaneous lupus erythematosus)
• Acute myeloid leukemia
• Multiple myeloma
• Solid tumors (non-small cell lung cancer, prostate cancer, colorectal cancer)
• Diffuse large B-cell lymphoma

Licensing and Integration

• A Thales platform license empowers users with advanced simulation capabilities, including dynamic patient pipeline management and precise emulation of clinical trial protocols to support informed drug development decisions.
• Pre-existing QSP models are meticulously validated and optimized to simulate complex biological systems and drug interactions, and are licensed separately from the Thales platform itself.
• Simulations Plus offers the ability to import existing QSP models into the Thales platform, enabling innovative integration solutions that extend and elevate in-house research capabilities.

Thales is positioned as a comprehensive multi-tool for QSP teams seeking standardization and scalability in their modeling operations, with expert support available from Simulations Plus's QSP leadership team to help organizations adopt and maximize the platform for their specific drug development needs.